TN2009000510A1 - Extended release formulation of nevirapine - Google Patents

Extended release formulation of nevirapine

Info

Publication number: TN2009000510A1
Authority: TN; Tunisia
Prior art keywords: nevirapine; extended release; release formulation; pharmaceutical composition; relates
Prior art date: 2007-06-08

Application number

TNP2009000510A

Other languages

English (en)

Inventor

Michael L Cappolla

Sveltana Sienkiewicz

Glenn Charles Snow

Feng-Jing Chen

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-08

Filing date

2009-12-04

Publication date

2011-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000510(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-04 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2011-03-31 Publication of TN2009000510A1 publication Critical patent/TN2009000510A1/fr

Links

NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 title abstract 4
238000013265 extended release Methods 0.000 title abstract 2
229960000689 nevirapine Drugs 0.000 title abstract 2
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TNP2009000510A 2007-06-08 2009-12-04 Extended release formulation of nevirapine TN2009000510A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94276507P	2007-06-08	2007-06-08
PCT/US2008/065705 WO2008154234A2 (fr)	2007-06-08	2008-06-04	Formulation à libération prolongée de névirapine

Publications (1)

Publication Number	Publication Date
TN2009000510A1 true TN2009000510A1 (en)	2011-03-31

Family

ID=39739795

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000510A TN2009000510A1 (en)	2007-06-08	2009-12-04	Extended release formulation of nevirapine

Country Status (29)

Country	Link
US (1)	US8460704B2 (fr)
EP (1)	EP2155169B1 (fr)
JP (1)	JP5417662B2 (fr)
KR (1)	KR101017862B1 (fr)
CN (1)	CN101784263B (fr)
AR (1)	AR066924A1 (fr)
AU (1)	AU2008262031B2 (fr)
BR (1)	BRPI0811732A2 (fr)
CA (1)	CA2687491C (fr)
CL (1)	CL2008001678A1 (fr)
CO (1)	CO6150128A2 (fr)
DK (1)	DK2155169T3 (fr)
EA (1)	EA018377B1 (fr)
EC (1)	ECSP099561A (fr)
ES (1)	ES2574836T3 (fr)
HK (1)	HK1145806A1 (fr)
HU (1)	HUE028598T2 (fr)
IL (1)	IL199924A0 (fr)
MA (1)	MA31430B1 (fr)
MX (1)	MX2009007764A (fr)
NZ (1)	NZ578664A (fr)
PE (2)	PE20090371A1 (fr)
PL (1)	PL2155169T3 (fr)
TN (1)	TN2009000510A1 (fr)
TW (1)	TWI419716B (fr)
UA (1)	UA97971C2 (fr)
UY (1)	UY31128A1 (fr)
WO (1)	WO2008154234A2 (fr)
ZA (1)	ZA200904939B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
CN101784263B (zh)	2007-06-08	2012-11-07	贝林格尔.英格海姆国际有限公司	奈韦拉平的延长释放制剂
EP3412300A1 (fr)	2008-06-27	2018-12-12	Duke University	Agents thérapeutiques comprenant des peptides de type élastine
WO2012164241A1 (fr)	2011-05-30	2012-12-06	Cipla Limited	Composition pharmaceutique antirétrovirale
EP4295858A1 (fr) *	2011-08-24	2023-12-27	ImmunoForge Co., Ltd.	Formulations des principes actifs destinées à la libération prolongée
AU2013229274A1 (en) *	2012-03-05	2014-09-04	Cipla Limited	Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
CN104523630B (zh) *	2015-01-22	2017-08-25	山东新时代药业有限公司	一种奈韦拉平片剂
EP3153157A1 (fr)	2015-10-09	2017-04-12	Teva Pharmaceutical Works Private Limited Company	Composition pharmaceutique à libération prolongée de névirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5366972A (en)	1989-04-20	1994-11-22	Boehringer Ingelheim Pharmaceuticals, Inc.	5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en)	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
CA2030056C (fr)	1989-11-17	1995-10-17	Karl D. Hargrave	5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines et leur utilisation pour la prevention ou le traitement de l'infection par le hiv
US5419917A (en) *	1994-02-14	1995-05-30	Andrx Pharmaceuticals, Inc.	Controlled release hydrogel formulation
US6514530B2 (en) *	1997-09-09	2003-02-04	Alza Corporation	Dosage form comprising means for changing drug delivery shape
DK1035834T3 (da)	1997-12-05	2002-07-08	Alza Corp	Osmotisk doseringsform omfattende en første og anden coating
CA2354472C (fr)	1998-12-17	2009-02-24	Alza Corporation	Transformation de capsules de gelatine remplies de fluide en systemes a liberation regulee a l'aide de revetements multiples
CZ2006443A3 (cs) *	1999-03-31	2019-02-20	Janssen Pharmaceutica N. V.	Hydrofilní formulace s řízeným uvolňováním, která obsahuje předželatinovaný škrob, způsob její přípravy a léková forma s jejím obsahem
PL207590B1 (pl) *	1999-09-24	2011-01-31	Janssen Pharmaceutica Nv	Cząstka stanowiąca dyspersję stałą oraz postać dawkowania, sposób ich otrzymywania i zastosowanie
AU2084801A (en)	1999-12-09	2001-06-18	Alza Corporation	Antiviral medication
US6541014B2 (en) *	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
WO2002092095A1 (fr)	2001-05-11	2002-11-21	Boehringer Ingelheim International Gmbh	Utilisation de nevirapine pour traiter ou prevenir des pathologies lipidiques chez des patients presentant une infection par vih resistante a la nevirapine
US20030050620A1 (en)	2001-09-07	2003-03-13	Isa Odidi	Combinatorial type controlled release drug delivery device
WO2004043435A2 (fr)	2002-11-13	2004-05-27	Control Delivery Systems, Inc.	Administration systemique d'agents antiviraux
EP1643946A2 (fr)	2003-06-20	2006-04-12	Viral Genomix, Inc.	Compositions et procedes de traitement du vih
ES2286716T3 (es)	2003-10-01	2007-12-01	Lupin Limited	Composicion farmaceutica de liberacion controlada y proceso para preparar la misma.
NZ547619A (en)	2003-11-13	2009-06-26	Psivida Inc	Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
WO2006024668A1 (fr) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US20110104267A1 (en) *	2005-04-25	2011-05-05	Aurobindo Pharma Limited	Pharmaceutical compositions of antiretrovirals
WO2007000779A2 (fr)	2005-06-29	2007-01-04	Panacea Biotec Ltd.	Nouvelles compositions pharmaceutiques a liberation prolongee et procedes pour leur preparation
EP1906937B1 (fr) *	2005-07-22	2016-10-19	Rubicon Research Pvt Ltd.	Nouvelle composition de comprimé dispersible
FR2891459B1 (fr)	2005-09-30	2007-12-28	Flamel Technologies Sa	Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CN101309675A (zh)	2005-10-14	2008-11-19	微量技术有限公司	口服剂量组合的药品包装
CN101784263B (zh)	2007-06-08	2012-11-07	贝林格尔.英格海姆国际有限公司	奈韦拉平的延长释放制剂

2008
- 2008-06-04 CN CN2008800193577A patent/CN101784263B/zh active Active
- 2008-06-04 MX MX2009007764A patent/MX2009007764A/es active IP Right Grant
- 2008-06-04 NZ NZ578664A patent/NZ578664A/en not_active IP Right Cessation
- 2008-06-04 EP EP08756672.5A patent/EP2155169B1/fr not_active Revoked
- 2008-06-04 BR BRPI0811732-2A2A patent/BRPI0811732A2/pt not_active IP Right Cessation
- 2008-06-04 CA CA2687491A patent/CA2687491C/fr active Active
- 2008-06-04 UA UAA200908230A patent/UA97971C2/ru unknown
- 2008-06-04 AU AU2008262031A patent/AU2008262031B2/en not_active Ceased
- 2008-06-04 KR KR1020097016610A patent/KR101017862B1/ko active Active
- 2008-06-04 DK DK08756672.5T patent/DK2155169T3/en active
- 2008-06-04 ES ES08756672.5T patent/ES2574836T3/es active Active
- 2008-06-04 JP JP2009552940A patent/JP5417662B2/ja active Active
- 2008-06-04 WO PCT/US2008/065705 patent/WO2008154234A2/fr active Application Filing
- 2008-06-04 HU HUE08756672A patent/HUE028598T2/en unknown
- 2008-06-04 PL PL08756672.5T patent/PL2155169T3/pl unknown
- 2008-06-04 US US12/523,226 patent/US8460704B2/en active Active
- 2008-06-04 EA EA200900958A patent/EA018377B1/ru not_active IP Right Cessation
- 2008-06-06 PE PE2008000969A patent/PE20090371A1/es not_active Application Discontinuation
- 2008-06-06 CL CL2008001678A patent/CL2008001678A1/es unknown
- 2008-06-06 AR ARP080102446A patent/AR066924A1/es unknown
- 2008-06-06 UY UY31128A patent/UY31128A1/es not_active Application Discontinuation
- 2008-06-06 PE PE2013000070A patent/PE20131035A1/es not_active Application Discontinuation
- 2008-06-06 TW TW097121294A patent/TWI419716B/zh active
2009
- 2009-07-15 ZA ZA200904939A patent/ZA200904939B/xx unknown
- 2009-07-16 IL IL199924A patent/IL199924A0/en unknown
- 2009-07-21 CO CO09075419A patent/CO6150128A2/es unknown
- 2009-08-05 EC EC2009009561A patent/ECSP099561A/es unknown
- 2009-12-04 TN TNP2009000510A patent/TN2009000510A1/fr unknown
- 2009-12-07 MA MA32400A patent/MA31430B1/fr unknown
2011
- 2011-01-05 HK HK11100032.7A patent/HK1145806A1/xx unknown

Also Published As

Publication number	Publication date
CA2687491A1 (fr)	2008-12-18
JP5417662B2 (ja)	2014-02-19
HUE028598T2 (en)	2016-12-28
KR101017862B1 (ko)	2011-03-04
TW200916127A (en)	2009-04-16
WO2008154234A2 (fr)	2008-12-18
AR066924A1 (es)	2009-09-23
IL199924A0 (en)	2010-04-15
US8460704B2 (en)	2013-06-11
EP2155169A2 (fr)	2010-02-24
CA2687491C (fr)	2011-09-20
TWI419716B (zh)	2013-12-21
KR20100020447A (ko)	2010-02-22
CL2008001678A1 (es)	2009-09-11
PE20090371A1 (es)	2009-04-24
HK1145806A1 (en)	2011-05-06
JP2010520891A (ja)	2010-06-17
MX2009007764A (es)	2009-09-10
PE20131035A1 (es)	2013-10-01
DK2155169T3 (en)	2016-06-13
BRPI0811732A2 (pt)	2014-11-18
UA97971C2 (ru)	2012-04-10
EA018377B1 (ru)	2013-07-30
NZ578664A (en)	2011-11-25
CN101784263A (zh)	2010-07-21
MA31430B1 (fr)	2010-06-01
ES2574836T3 (es)	2016-06-22
PL2155169T3 (pl)	2016-09-30
CO6150128A2 (es)	2010-04-20
EP2155169B1 (fr)	2016-03-23
ZA200904939B (en)	2010-04-28
CN101784263B (zh)	2012-11-07
WO2008154234A9 (fr)	2009-11-26
ECSP099561A (es)	2009-09-29
AU2008262031B2 (en)	2011-08-25
EA200900958A1 (ru)	2010-04-30
AU2008262031A1 (en)	2008-12-18
UY31128A1 (es)	2009-01-30
US20100278918A1 (en)	2010-11-04
WO2008154234A3 (fr)	2010-01-21

Publication	Publication Date	Title
JOP20180102A1 (ar)	2019-01-30	مركب صيدلاني
TN2009000510A1 (en)	2011-03-31	Extended release formulation of nevirapine
MX2011007267A (es)	2011-08-15	Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
MX2012007098A (es)	2012-07-20	Derivados fenolicos y su uso farmaceutico o cosmetico.
PH12012501346A1 (en)	2012-12-17	Heteroaryl compounds and uses thereof
EA201101118A1 (ru)	2012-03-30	Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
MX2012007161A (es)	2012-07-03	Derivados fenolicos y su uso farmaceutico o cosmetico.
IL224288A (en)	2015-02-26	Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
MX2011014019A (es)	2012-02-22	Derivados de diazahomoadamantano y sus metodos de uso.
MY153915A (en)	2015-04-15	Organic compounds
LT2373681T (lt)	2017-04-10	Albiglutido farmacinės kompozicijos
PL2079446T3 (pl)	2012-04-30	Preparat paliperidonu o przedłużonym uwalnianiu
HK1142608A1 (en)	2010-12-10	5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
HK1133642A1 (en)	2010-04-01	Azaadamantane ester and carbamate derivatives and methods of use thereof
WO2009115084A3 (fr)	2010-04-08	Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
IN2012DN03404A (fr)	2015-10-23
ZA201102652B (en)	2012-01-25	Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormane (gnrh) as immunogen
MX2010008852A (es)	2010-09-24	Formulaciones de flibanserina.
MX2009010176A (es)	2009-10-12	Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
EP2296687A4 (fr)	2012-12-26	Compositions pharmaceutiques de conjugués somatostatine-dopamine
MY165088A (en)	2018-02-28	Pharmaceutical compositions comprising alisporivir
IL212171A (en)	2015-11-30	1-Phenylpyrol compounds, pharmaceuticals containing them and their use
AP2012006119A0 (en)	2012-02-29	Pharmaceutical composition of isoniazid.
MX2012008253A (es)	2012-08-15	Uso farmaceutico de compuestos multiciclicos como agentes anti-sindrome de inmunodeficiencia adquirida.
EP2568810A4 (fr)	2013-12-04	Compositions de darunavir